# Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

> **NCT05355168** · PHASE2 · COMPLETED · sponsor: **Anhui Provincial Hospital** · enrollment: 35 (actual)

## Conditions studied

- Toxicity, Drug

## Interventions

- **DRUG:** neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery

## Key facts

- **NCT ID:** NCT05355168
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355168, "Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05355168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*